

“Specific Diagnostics Announces Sponsored Research Agreement with the University of Versailles-St Quentin in Paris, France”

October 9, 2020 - MOUNTAIN VIEW, California – FOR IMMEDIATE RELEASE

Specific Diagnostics today announced it has entered into a sponsored agreement with the University of Versailles-Saint-Quentin-En-Yvelines to conduct a year-long study to evaluate the performance of the Reveal Rapid AST System and consumable assays. Current methodologies require at least one day to determine the effective antibiotic while the Reveal instrument provides antibiotic susceptibility results in an average of 5 hours, allowing same-shift impact.

This agreement enables the university to employ a full-time research assistant under the supervision of Dr. Martin Rottman, who runs a lab in the Infection and Inflammation Unit at the University and INSERM (French National Institute of Health and Medical Research). The research assistant will lead the study over a 12-month period in volunteer bacteriology laboratories in the Greater Paris area.

“This study comes at an exciting time for our company, as it coincides with our European market launch,” said Dr. Paul A. Rhodes, CEO of Specific. “The world needs affordable, rapid susceptibility testing to treat time critical infections and we look forward to the evaluation relationship with leaders at the University of Versailles, led by Professor Martin Rottman.”

“We’ve already seen the Reveal system produce accurate results compared to the current method of MIC determination,” said Dr. Rottman. “We’re excited for the opportunity to gain a greater understanding of the impact the Reveal AST System can have on treatment of patients experiencing blood infections, and Specific Diagnostics will greatly contribute to these breakthroughs.”

Specific’s Reveal furnishes a phenotypic MIC directly from a positive blood culture sample in an average of under 5 hours, according to a recently announced study (Tibbetts et al, ECCMID 2020). Based upon arrays of printed sensors responsive to the volatiles emitted by growing microorganisms, the Reveal system has a high throughput, low cost, broad and flexible antibiotic menu, and ease of use to prompt wide adoption.

About Specific

Specific Diagnostics has developed *in vitro* diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they growth in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Specific is based in Mountain View, CA.



For press inquiries, please contact: press@specificdx.com